pharma news

News

Novartis gets win for another Avidity muscular dystrophy AOC

Novartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.

News

Basketball great Shaq fronts Lilly sleep apnoea campaign

Eli Lilly has recruited basketball legend Shaquille O'Neal to promote a sleep apnoea awareness campaign and make the case for treatment with Zepbound.

News

Anthropic puts life sciences at heart of new AI model

Anthropic has released Claude Fable 5, trumpeting its R&D credentials, but has faced a backlash over "safeguards" built into the model.

News

SonoThera's $125m Series B heads recent biofinancings

Our latest roundup of financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics.

News

Lilly wins new FDA approval for eczema drug Ebglyss

Lilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.

News

Bayer's asundexian starts EU review for ischaemic stroke

The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.

Novartis gets win for another Avidity muscular dystrophy AOC

Basketball great Shaq fronts Lilly sleep apnoea campaign

Anthropic puts life sciences at heart of new AI model

SonoThera's $125m Series B heads recent biofinancings

Lilly wins new FDA approval for eczema drug Ebglyss

Bayer's asundexian starts EU review for ischaemic stroke

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks